Inside the Unapproved 'Wolverine' Peptide Stack

The so-called “Wolverine” peptide stack combines two synthetic peptides: BPC-157 and TB-500, a fragment of thymosin beta-4. Peptides are short chains of amino acids, and the body produces many naturally. Some peptide drugs, such as insulin and GLP-1 receptor agonists, are FDA-approved for specific conditions. The Wolverine stack is not one of them.

Neither BPC-157 nor TB-500 has received FDA approval, and neither has reached human clinical trials. Research remains in early, preclinical stages. A 2025 review of non-human studies noted a potential role for BPC-157 in musculoskeletal symptoms, but none of the reviewed studies provided clinical safety evidence. For TB-500, animal and test-tube research has suggested improved wound healing through a metabolite, but those findings have not been confirmed in humans.

Because the stack is usually injected, either under the skin or into muscle, it carries risks that go beyond the lack of proven benefit. Injecting bypasses protective barriers in the skin, gut and lungs, and unregulated manufacturing raises contamination and infection risks. Reported side effects include injection site irritation, stomach upset, lethargy and headaches, while longer-term risks, including effects on the immune system or cancer risk, remain unknown.

What the Evidence Actually Shows on BPC-157 and TB-500

Why BPC-157 Has Not Moved Past Animal Models

The most commonly cited BPC-157 review is based on preclinical work, not human trials. The 2025 review suggested possible musculoskeletal benefit but explicitly found no clinical safety evidence. An earlier 2021 rodent study reported reduced pain and improved muscle and nerve healing, but the effect appeared in only one stage of the study. That inconsistency weakens the case for a reliable effect in people.

Advertisement

TB-500's Wound-Healing Signal Remains in Test Tubes and Animals

TB-500's proposed benefit runs through a metabolite known as Ac-LKKTE, which may improve wound healing. However, the supporting studies were conducted in test tubes and animal models. Findings at that stage can translate to humans, but high-quality human trials are still required to prove it. Until then, the human evidence is anecdotal, not clinical.

Injection Changes the Risk Profile

Influencers often recommend subcutaneous or intramuscular injection, but healthcare professionals caution against it. Injection bypasses the immune barriers that topical application leaves partially intact, and because the products are unregulated, needle contamination and the introduction of harmful substances are real hazards. There is also a theoretical concern: if these peptides encourage the growth of blood vessels to aid healing, they could potentially nourish precancerous cells in someone who already has them. No human safety trials have ruled this out.

How to Vet a 'Wolverine Stack' Claim Before Trying It

  • Verify approval status first. BPC-157 and TB-500 are not FDA-approved, so any seller claiming otherwise should be treated as unreliable. Ask for the clinical trial data rather than influencer testimonials.
  • Avoid injected versions. Injection bypasses protective barriers and carries contamination and infection risks, making that route materially more dangerous than topical application.
  • If you are a competitive athlete, steer clear. Both peptides are banned by the World Anti-Doping Agency, so use could create a doping violation even without proven performance benefit.
  • Discuss the stack's theoretical tumor risk with your doctor. The blood-vessel growth mechanism has not been tested in humans; anyone with a history of precancerous changes should be especially cautious.
  • Do not treat anecdotal recovery claims as evidence of safety. Only approved peptide drugs such as insulin and GLP-1s have been through the structured FDA safety review process.